Proximal tubular impairment in HIV-positive patients receiving tenofovir disoproxil fumarate, and association between tenofovir concentration and urinary retinol binding protein (RBP) levels

Trial Profile

Proximal tubular impairment in HIV-positive patients receiving tenofovir disoproxil fumarate, and association between tenofovir concentration and urinary retinol binding protein (RBP) levels

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2015

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 09 Dec 2015 New trial record
    • 03 Dec 2015 Results published in the AIDS
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top